Chain Pharmaceuticals GmbH Announces Its Phytocannabinoid Drug Discovery Platform
Company Will Pursue Drug Discovery of Market-Authorized, Finished Pharmaceuticals that Address Demand for Personalized Therapies
FRANKFURT AM MAIN, Germany, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Dr. Pierre Debs, Ph.D. announced today the launch of Chain Pharmaceuticals GmbH, a phytocannabinoid drug discovery company leveraging machine learning and real world medical data in the development of clinically proven plant-based medicines for market authorization. Bringing together pharmaceutical, medical, cannabis and digital experts, Chain Pharmaceuticals brings a unique platform and process to expedite the process of design and execution of clinical trials for cannabis based molecules, without waiting 10 years and at enormous cost. Chain Pharmaceuticals will release a series of unique and differentiated solventless extract-based products for the current regulations throughout the European Union in the coming year. Chain extracts are designed with a purpose and play an integral role in tracking efficacy and patient usage outcomes.
The Chain Pharmaceuticals ecosystem is driven by five major trends shaping the future of medicine:
- The power of machine learning, artificial intelligence and in silico modeling to expedite and reduce the cost of drug discovery
- The ability of blockchain to facilitate data-gathering and patient engagement
- Harnessing the power of real world, evidence based data in the design of health care therapies
- Increased desire for and expanded use of plant-based pharmaceuticals
- The advances and momentum in personalized medicine as a leading paradigm in health care
“Our core energies are focused on bringing plant-based pharmaceutical products to the market in an expedited time frame with higher efficiencies, less up-front costs, longer-term equitable returns, and in a sustainable manner. Clinically proven market authorized medications are sine qua non for long-term demands of all stake-holders throughout European healthcare systems,” explains Dr. Pierre Debs, Founder and Chief Executive Officer of Chain Pharmaceuticals GmbH.
Co-Founder and CIO Dr. Pavel Kubů, MD explains, “Decentralized and personalized phytocannabinoid-based healthcare solutions require GDPR compliant, transparent, rapid, targeted data acquisition and analysis. Our HealChain App is the synergistic meeting point for data from real world usage, continually updated cannabis patient usage and a broad palate of machine learning driven resources specifically designed for each subscriber.”
Phytocannabinoids: a unique but challenging resource
Cannabis’ panoply of hundreds of natural pharmaceutical active ingredients makes it a unique resource for research and development. Virtually non-toxic and devoid of serious side effects, in a controlled medical environment, the plant is an ideal starting material for personalized medicines. However, cannabinoid-based drug development has been a challenge as it does not fit neatly into the standard paradigm for market authorization if one considers more than a single molecule for a single medication. Meanwhile, different patients use different whole-cannabis products for the same indication, or the same product for multiple indications. Health care providers need to work with over 200+ varieties of generic cannabis products on the market with relatively little pharmacological justification other than it has THC and seems to work, and only 3 market authorized products.
Machine Learning/Artificial Intelligence for modern, rapid drug discovery
Chain Pharmaceuticals will overcome these hurdles and capture the current market opportunities around phytocannabinoids by leveraging machine learning, artificial intelligence and in silico modeling to expedite the design and execution of a portfolio of clinical trials. By rationalizing established anecdotal evidence, utilizing real world data and other inputs to feed a machine learning platform, Chain Pharmaceuticals’ model will drive fast, efficient phytocannabinoid compound identification and the related targetable clinical indications. “We started our discovery pipeline last year, targeting four indications and one bio-medical product, and have progressed through the mid-stages of in silico discovery – once the real world data is infused, we anticipate several exciting outcomes,” said Debs.
Leadership and partnerships in place
Chain Pharmaceuticals’ leadership team has extensive experience in drug development and clinical trials. Dr. Pierre Debs has over twenty years of experience in stem cell research and opened the European market, in particular Germany, for import and distribution licenses for Canadian cannabis flower. Joining Dr. Debs on the Chain Pharmaceuticals’ executive team and as co-founder is medical informatics and addictology expert Dr. Pavel Kubů, MD, formerly of the Intel Corporation and Founding CEO of the International Cannabis and Cannabinoids Institute in Prague; Dr. Martin Votava, MD, Ph.D., a pharmacology, regulatory science and pharmacovigilance expert who has held positions at EMA's scientific committee CHMP, PrimeVigilance and associate professor of pharmacology at Charles University’s Medical school in Prague; Dr. Daniel Smutek, MD, Ph.D., MSc., also of Charles University and the former Senior Medical Director of PAREXEL.
The Company also has powerful strategic partnerships in place, including with Innoplexus AG as its exclusive machine learning/AI provider for rationalizing petabytes of existing scientific and medical data as well as real world usage data in the phytocannabinoid drug discovery process. Chain Pharmaceuticals’ patient data-gathering app, HealChain, is designed with Innoplexus’ app and its capabilities of data extraction with AI algorithms. It will accelerate its own research and insights, and utilize existing research and anecdotal evidence through an established Innoplexus-driven machine learning system custom built for drug discovery that will regularly update, test and refine insights on compounds with a high likelihood of efficacy.
HealChain, which will launch in the coming months, will serve as one of the feeds for the machine learning systems by incentivizing medical cannabis patients to share data for the design of clinical trials with patients owning and licensing their anonymized data. The HealChain app is a joint venture between Chain Pharmaceuticals and Innoplexus, based on the latter’s Curia and Neuria apps.
About Chain Pharmaceuticals GmbH:
Chain Pharmaceuticals GmbH is a German-based drug discovery company using real world data, machine-learning and artificial intelligence to rapidly design and execute clinical trials leading to market-authorized phytocannabinoid products. Founded in 2021, Chain Pharmaceuticals' directive is to be a leader in decentralized and personalized phytocannabinoid-based healthcare solutions through development of an innovative portfolio of plant based-pharmaceutical products. The company’s app, HealChain, employs blockchain technology and tokenization to engage and incentivize patients to share their personal health data while retaining ownership and control. This patient-staked approach and involvement ensures transparency in clinical trial design and execution. To learn more, please visit www.chainpharmaceuticals.com.
About Dr. Pierre Debs
Dr. Debs co-founded MedCann GmbH, a German federally-licensed importer, manufacturer and distributor of medical cannabis products, in 2015, and was the first company in Europe/Germany to import and distribute Canadian medical cannabis flowers. He has over twenty years’ experience in stem cell research, including endocannabinoid system function. Along with his MedCann co-founder, Dr. Debs opened the current medical market in Germany in particular, but with immediate impact throughout Europe; and beat other established companies to obtain the first import license for Canadian flower.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Ministry of Industry and Mineral Resources Announces Details of Third Edition of Future Minerals Forum11.12.2023 19:36:14 CET | Press release
RIYADH, Saudi Arabia, Dec. 11, 2023 (GLOBE NEWSWIRE) -- At a press conference today, the Ministry of Industry and Mineral Resources (MIM) announced details of the third edition of the Future Minerals Forum (FMF), to be held in Riyadh 9th-11th January at the King Abdulaziz International Conference Center. Speaking at the conference, H.E. the Vice Minister for Mining Affairs, Khalid Al-Mudaifer, looked forward to further achievements delivered by the Ministerial Roundtable and FMF 2024. In previous editions, both platforms have seen participation from ministers and a leading group of international speakers to address issues and turn talk into action. The Vice Minister discussed the unique role of the FMF in hosting the only Ministerial Roundtable of its kind in the industry. He said: "We have succeeded in making this meeting a strategic and influential platform led by governments, providing a voice for many countries and official organizations." Over 70 countries will be represented by g
Mendus presenterar positiva överlevnadsdata från fas 2-studien ADVANCE II som utvärderar vididencel som underhållsbehandling vid AML vid ASH-konferensen11.12.2023 19:30:00 CET | Pressemelding
Pressmeddelande Stockholm, 11 december 2023 Per den 24 november 2023 var återfallsfri medianöverlevnad (mRFS) 30,4 månader Medianen för totalöverlevnad (mOS) hade inte ännu inte uppnåtts, med majoriteten av patienterna (14/20) fortfarande i livet Minskning av mätbar av mätbar restsjukdom (MRD) och induktion av immunsvar korrelerar med fördelar för RFS och OS, vilket bekräftar vididencels verkningsmekanism Virtuellt Key Opinion Leader-event (KOL) med huvudprövare för att diskutera nya ASH-data torsdagen den 14 december 2023 kl. 15.00 CET, anmäl här Mendus AB (“Mendus” publ; IMMU. ST), ett biofarmabolag med fokus på immunterapier riktade mot tumöråterfall, presenterade idag positiva uppdaterade överlevnadsdata från fas 2-studien ADVANCE II som utvärderar vididencel (DCP-001) vid akut myeloid leukemi (AML), vid konferensen American Society of Hematology’s Annual Meeting (ASH 2023). Data från långtidsuppföljningen visade varaktiga behandlingssvar med överlevnadsnytta som överstiger histori
Mendus announces positive survival data from Phase 2 ADVANCE II trial evaluating vididencel as maintenance therapy for AML at ASH 202311.12.2023 19:30:00 CET | Press release
Press Release Stockholm, Sweden, December 11, 2023 As of November 24, 2023, median relapse-free survival (mRFS) stood at 30.4 months Median overall survival (mOS) was not reached, with the majority of patients (14/20) still alive Reduction in measurable residual disease (MRD) and induction of immune responses correlate with RFS and OS benefit, confirming vididencel mechanism of action Virtual KOL event with principal investigator to discuss new ASH data on Thursday, December 14, 2023, at 9.00 am ET/3.00 pm CET; register HERE Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced positive updated survival data from the Phase 2 ADVANCE II trial evaluating vididencel (DCP-001) in acute myeloid leukemia (AML) at the American Society of Hematology’s 65th Annual Meeting (ASH 2023). The longer-term follow up data showed durable treatment responses with survival benefit exceeding historical results expected from t
Harbert Management Corporation included in 2023 Pensions & Investments Best Places to Work in Money Management11.12.2023 19:28:04 CET | Press release
BIRMINGHAM, Ala., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Harbert Management Corporation (“HMC”) has been voted one of the Best Places to Work in Money Management for the fifth year in a row. Presented by Pensions & Investments, the global news source of money management and institutional investing, the 12th annual survey and recognition program is dedicated to identifying and recognizing the best employers in the money management industry. HMC prides itself on its history of managing the firm and investment strategies with the utmost integrity. For 30 years HMC has been devoted to investing capital in a responsible manner. We are committed to corporate social responsibility and engaging our employees and stakeholders to pursue opportunities that make positive and long-lasting impacts. Investment excellence, transparency with our clients, and exemplary Fund Administration are the hallmarks of HMC’s commitment to investors. “Pensions & Investments is proud to honor the Best Places to Work in
Holding(s) in Company11.12.2023 18:11:50 CET | Press release
TORONTO, Canada, Dec. 11, 2023 (GLOBE NEWSWIRE) -- TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:Amaroq Minerals Ltd.1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)Non-UK issuerX2. Reason for the notification (please mark the appropriate box or boxes with an “X”)An acquisition or disposal of voting rightsXAn acquisition or disposal of financial instrumentsAn event changing the breakdown of voting rightsOther (please specify):3. Details of person subject to the notification obligationNameAkta sjóðir hf., an alternative investment fund manager and a UCITC management company, acting on behalf of funds operated by the company.City and country of registered office (if applicable)Reykjavík, Iceland4. Full name of sha